March 25, 2011

Dear Provider,

Last year, Pfizer and King Pharmaceuticals announced that they entered into an agreement for Pfizer to acquire King Pharmaceuticals. The acquisition closed effective Tuesday, March 1, 2011, after which King Pharmaceuticals ceased to be an independent company. We want to let you know what the acquisition means for independent medical education grant submissions moving forward.

We will, of course, continue to honor the terms of any existing Letters of Agreement for grants previously approved by King. Updated educational needs areas of support for 2011 have been published. This posting includes new clinical area goals of interest added as a result of the recent King Pharmaceuticals acquisition.

Going forward, we will follow the current Pfizer policies and procedures with respect to independent educational grants, which can be found at www.pfizermededgrants.com. This website also includes a comprehensive resource center, important timelines for applying for a grant, information on how decisions are made, and other relevant information. We encourage your continued interest in accelerating the translation of clinical science into quality patient care.

Please direct any queries to the Pfizer Medical Education Group via the email address listed below.

Sincerely,

Pfizer Medical Education Group (MEG)
mededgrants@pfizer.com

King is now part of Pfizer. The integration of King and Pfizer entities may be pending in various local jurisdictions and integration may be subject to completion of various local legal and regulatory obligations. All content in this message is subject to works council and/or union consultations, if applicable, and other legal requirements where appropriate.